Cyclooxygenase-2 gene polymorphisms and the risk of colorectal cancer: A population-based study

Li,Hongxia; Guo,Qinyue; Zhou,Bo; He,Shuixiang

doi:10.3892/ol.2015.3477

Cyclooxygenase-2 gene polymorphisms and the risk of colorectal cancer: A population-based study

Authors:
- Hongxia Li
- Qinyue Guo
- Bo Zhou
- Shuixiang He
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Respiration, The First Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: July 9, 2015 https://doi.org/10.3892/ol.2015.3477
Pages: 1863-1869

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the association between polymorphisms in the cyclooxygenase-2 (COX-2) gene promoter region, rs20417 G/C and rs2745557 G/A, and the susceptibility to colorectal cancer (CRC) in a Han Chinese population in Shaanxi, China. Polymerase chain reaction and restriction fragment length polymorphism (PCR‑RFLP) were used to detect the polymorphisms of COX‑2, rs20417 G/C and rs2745557 G/A, in 300 patients with CRC and 300 healthy individuals in the present case‑control study. The results revealed that for the COX‑2 rs20417 G/C polymorphism, the GC+CC allele frequency was 80% in CRC patients and 71% in healthy controls [odds ratio (OR)=1.63; 95% confidence interval (CI), 1.12‑2.38; P=0.01]. For the COX‑2 rs2745557 G/A polymorphism, the GA+AA allele frequency was 84% in CRC patients and 73% in healthy controls (OR=1.94; 95% CI, 1.30‑2.90; P<0.01). In addition, among individuals with a smoking history, drinking history or family history of CRC, those who were COX‑2 rs20417 (GC+CC) or COX‑2 rs2745557 (GA+AA) carriers had a significantly increased risk of developing CRC compared with that of GG genotype carriers (P<0.05). Furthermore, the allelic frequencies of COX‑2 rs20417 G/C and rs2745557 G/A in patients with lymph node metastasis in stage Ⅲ/Ⅳ of CRC were significantly different from those of COX‑2 rs20417 G/C and rs2745557 G/A in patients without lymph node metastasis in stage Ⅰ/Ⅱ (P<0.05). In conclusion, the results of the present study revealed that COX‑2 rs20417 C allele carriers and rs2745557 A allele carriers have a significantly increased risk of CRC compared with GG genotype carriers; in addition, the frequencies of these alleles were demonstrated to be associated with lymph node metastasis and CRC progression.

View Figures

View References

1	Lashner BA, Silverstein MD and Hanauer SB: Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci. 34:1536–1541. 1989.
2	Lennard-Jones JE, Morson BC, Ritchie JK, et al: Cancer in colitis: Assessment of the individual risk by clinical and histological criteria. Gastroenterology. 73:1280–1289. 1977.PubMed/NCBI
3	Rhodes JM and Campbell BJ: Inflammation and colorectal cancer: IBD associated and sporadic cancer compared. Trends Mol Med. 8:10–16. 2002. View Article : Google Scholar : PubMed/NCBI
4	Romano M and Claria J: Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: Implications for cancer therapy. FASEB J. 17:1986–1995. 2003. View Article : Google Scholar : PubMed/NCBI
5	Simmons DL, Botting RM and Hla T: Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 56:387–437. 2004. View Article : Google Scholar : PubMed/NCBI
6	Tsujii M, Kawano S, Tsuji S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:705–716. 1998. View Article : Google Scholar : PubMed/NCBI
7	Ranger GS, Thomas V, Jewell A and Mokbel K: Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 24:2349–2351. 2004.PubMed/NCBI
8	Eberhart CE, Coffey RJ, Radhika A, et al: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1183–1188. 1994.PubMed/NCBI
9	Ristimäki A, Honkanen N, Jänkälä H, et al: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1276–1280. 1997.PubMed/NCBI
10	Liu X, Li P, Zhang ST, et al: COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID. Dis Esophagus. 21:9–14. 2008.PubMed/NCBI
11	Brosens LA, Donahue CA, Keller JJ, et al: Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the −765 G/C COX-2 polymorphism. Clin Cancer Res. 11:4090–4096. 2005. View Article : Google Scholar : PubMed/NCBI
12	Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE and Bell DA: Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther. 299:468–476. 2001.PubMed/NCBI
13	Papafili A, Hill MR, Brull DJ, et al: Common promoter variant in cyclooxygenase-2 represses gene expression: Evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol. 22:1631–1636. 2002. View Article : Google Scholar : PubMed/NCBI
14	Hamajima N, Takezaki T, Matsuo K, et al: Genotype frequencies of cyclooxygenease 2 (COX2) rare polymorphisms for Japanese with and without colorectal cancer. Asian Pac. Asian Pac J Cancer Prev. 2:57–62. 2001.
15	Lee TS, Jeon YT, Kim JW, et al: Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population. Ann N Y Acad Sci. 1095:134–142. 2007. View Article : Google Scholar : PubMed/NCBI
16	Zhang X, Miao X, Tan W, et al: Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 129:565–576. 2005. View Article : Google Scholar : PubMed/NCBI
17	Szczeklik W, Sanak M, Szczeklik A, et al: Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol. 114:248–253. 2004. View Article : Google Scholar : PubMed/NCBI
18	Hermanek P, Scheibe O, Spiessl B and Wagner G: TNM classification of malignant tumors: The new 1987 edition. Rontgenblatter. 40:2001987.(In German). PubMed/NCBI
19	Hamilton SR, Bosman FT, Boffetta P, et al: Tumours of the colon and rectumWHO Classification of Tumours of the Digestive System. Bosman FT, Carneiro F, Hruban RH and Theise ND: IARC Press; Lyon: pp. 131–181. 2010
20	Koh WP, Yuan JM, Van Den Berg D, et al: Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: The Singapore Chinese Health Study. Br J Cancer. 90:1760–1764. 2004.PubMed/NCBI
21	Ulrich CM, Whitton J, Yu JH, et al: PTGS2 (COX-2) −765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev. 14:616–619. 2005. View Article : Google Scholar : PubMed/NCBI
22	Lin HJ, Keku TO, Reddy ST, et al: Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev. 11:1305–1315. 2002.PubMed/NCBI
23	Sansbury LB, Millikan RC, Schroeder JC, et al: COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs and risk of colon cancer in African Americans (United States). Cancer Causes Control. 17:257–266. 2006. View Article : Google Scholar : PubMed/NCBI
24	Goodman JE, Bowman ED, Chanock SJ, et al: Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 25:2467–2472. 2004. View Article : Google Scholar : PubMed/NCBI
25	Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F and Moreno V: Bellvitge Colorectal Cancer Study Group: Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer. 91:339–343. 2004.PubMed/NCBI
26	Tomozawa S, Tsuno NH, Sunami E, et al: Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer. 83:324–328. 2000. View Article : Google Scholar : PubMed/NCBI
27	Zhang H and Sun XF: Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol. 97:1037–1041. 2002. View Article : Google Scholar : PubMed/NCBI
28	Konno H, Baba M, Shoji T, Ohta M, Suzuki S and Nakamura S: Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis. 19:527–534. 2002. View Article : Google Scholar : PubMed/NCBI
29	Yao M, Lam EC, Kelly CR, Zhou W and Wolfe MM: Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer. 90:712–719. 2004. View Article : Google Scholar : PubMed/NCBI
30	Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increase metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997. View Article : Google Scholar : PubMed/NCBI